Antitumor activity
tumor
DISEASE PROGRESSION, TUMOR, CHOLANGIOCARCINOMA
Thirty-three of 39 patients were evaluable for tumor response by RECIST v1.1. Six patients were not evaluable because of early discontinuation due to disease progression (A patient with cholangiocarcinoma, treated with OBI-3424 at 10 mg/mReasons for discontinuation of the study drug for all patients were as follows: disease progression (